Core Viewpoint - Aladdin's stock has shown a significant increase in price and trading activity, indicating positive market sentiment and potential growth opportunities for investors [1][2]. Company Overview - Shanghai Aladdin Biochemical Technology Co., Ltd. was established on March 16, 2009, and went public on October 26, 2020. The company is located at 36 Nanta, New Jinqiao Road, Pudong New District, Shanghai [1]. - The main business activities include research, production, and sales of reagents, with revenue composition as follows: high-end chemicals 42.21%, life sciences 32.73%, analytical chromatography 13.78%, materials science 7.55%, laboratory consumables 2.01%, and others 1.72% [1]. Financial Performance - For the period from January to March 2025, Aladdin achieved a revenue of 130 million yuan, representing a year-on-year growth of 32.20%. The net profit attributable to shareholders was 24.18 million yuan, reflecting a year-on-year increase of 41.35% [2]. - Since its A-share listing, Aladdin has distributed a total of 241 million yuan in dividends, with 150 million yuan distributed over the past three years [3]. Shareholder Structure - As of March 31, 2025, the number of shareholders increased to 10,100, up by 6.08% from the previous period. The average circulating shares per person decreased by 5.73% to 27,331 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A (003095) by 3.37 million shares, and new entries from China Europe Innovation Future Mixed (LOF) (501208) and China Europe Science and Technology Theme Mixed (LOF) (501081) [3].

Core Viewpoint - The company has established an innovative platform in synthetic biology, focusing on core technologies such as strain modification, fermentation process optimization, and product separation and purification [1] Company Developments - The company is engaged in research and development of non-grain bio-based materials, food ingredients, and terpene derivatives, leveraging its synthetic biology base [1] - High-value aroma products, such as Valencia orange oil, have completed pilot-scale process validation and are currently exploring industrial production solutions [1] - The company aims to enhance cost reduction and efficiency improvements while consolidating its technological advantages and market positioning in the synthetic biology sector [1]

Core Insights - The approval status of RebM2, a steviol glycoside, in the domestic market has garnered investor attention, with the company actively pushing for subsequent approval processes after the public consultation phase ended on August 14 [1] - RebM2 has received GRAS certification from the FDA, allowing it to be legally sold in the U.S. food and beverage market, potentially becoming a new profit growth point for the company [1] - RebM2, developed through enzyme conversion, offers superior sweetness characteristics, a purer taste, better stability, and improved solubility compared to existing rare monomer components, making it a promising natural sweetener [1] Industry Developments - The industrialization of RM2 is seen as a milestone in the evolution of steviol glycosides, with RM2 being approximately 200 times sweeter than sucrose and exhibiting a favorable sweetness release curve [2] - RM2's formulation can optimize costs and enhance taste in reduced-sugar recipes, breaking through traditional limitations and expanding the market boundaries for steviol glycosides [2] - The enzyme conversion process has significantly improved the yield of rare monomers to over 75%, marking a shift from resource-dependent to technology-driven production in the natural sweetener industry [2] Company Innovations - RM2 is part of a broader strategy in synthetic biology, with the company also achieving breakthroughs in the complete synthesis of monk fruit sweet glycosides and advancements in the field of left-handed β-galactomannan [3] - The enzyme conversion method demonstrates the feasibility and application value of synthetic biology in the plant extract sector, enhancing supply chain stability and aligning with sustainable development goals [3] - The company is exploring a strategic transformation towards becoming a technology-driven health consumption technology enterprise through a dual approach of natural extraction and biological synthesis [3]

Core Viewpoint - As of August 20, 2025, Qingsong Co., Ltd. shares closed at 6.30 yuan, reflecting a decrease of 0.05 yuan or 0.79% from the previous trading day [1] Group 1: Stock Performance - The opening price for Qingsong Co., Ltd. was 6.36 yuan, with a highest price of 6.36 yuan and a lowest price of 6.26 yuan on the same day [1] - The trading volume reached 264,500 hands, with a total transaction value of 166 million yuan [1] Group 2: Industry Performance - The beauty and personal care sector showed active performance on the same day, with an overall increase of 2.42% and a net inflow of 351 million yuan from main funds [1] Group 3: Company Financials - Qingsong Co., Ltd. primarily operates in the cosmetics and disinfectant sectors, involving synthetic biology and concepts related to the Fujian region [1] - On the same day, the main funds experienced a net outflow of 18.576 million yuan, with a cumulative net outflow of 71.6218 million yuan over the past five days [1]

Core Viewpoint - The company is advancing the approval and market entry of its newly developed steviol glycoside, RebM2, which has received GRAS certification in the U.S. and is nearing domestic approval in China, indicating significant potential for growth in the natural sweetener market [1][2][3]. Group 1: Product Development and Market Potential - RebM2 is a rare, high-value steviol glycoside that meets the increasing demand for low-calorie, high-sweetness solutions in the context of global sugar reduction initiatives [2]. - The product offers a sweetness level 150 to 200 times that of sucrose, with zero calories and a favorable taste profile, addressing the limitations of traditional steviol glycosides [2][3]. - The company has successfully improved the production efficiency and cost-effectiveness of RebM2 through enzyme conversion methods, enhancing its solubility and stability [3]. Group 2: Strategic Importance and Future Plans - The completion of the public consultation phase for RebM2 in China is a crucial step for the company to accelerate its market promotion and sales efforts [3]. - The company plans to focus on the deep development of RebM2, aiming to innovate applications and expand its product matrix [4]. - The synthetic biology workshop is set to commence operations in September 2024, enabling mass production of RebM2 [3].

（文章来源：每日经济新闻） 天风证券8月20日发布研报称，给予嘉必优（688089.SH，最新价：28.4元）买入评级。评级理由主要包 括：1）主业——2025H1业绩高增长，受益多维因素驱动；2）拓新——合成生物+AI，加速新领域拓展 效率；3）研发方面，公司生物信息学平台已在本地部署了deepseek-R1大模型；4）成果方面，公司已 拥有较多产品储备，尤其在HMO领域。双方将结合时空多组学等组学技术。风险提示：国际贸易/食品 安全风险，投资及新业务、新产品开发不及预期。 ...

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6] Core Views - The company reported a revenue of 307 million yuan for the first half of 2025, representing a year-on-year increase of 17.60%, and a net profit of 108 million yuan, up 59.01% year-on-year [1] - The growth in revenue is primarily driven by increased sales of ARA and DHA products to domestic customers, supported by new national standards, fertility subsidies, and a shift in major clients from fish oil DHA to algae oil DHA [2] - The company has improved its profit margins significantly, with a gross margin nearing 50% and a net margin of 35%, both up by 8 and 9 percentage points respectively compared to the previous year [2] - The company is leveraging synthetic biology and AI to enhance its product offerings and expand into new application areas, including the development of high-value molecules and enzymes [3] - The company has a strong product pipeline, particularly in the HMO sector, with 2'-FL receiving approval and a production capacity of 200-300 tons per year [3] Financial Performance - For 2025, the company is projected to achieve total revenues of 702.42 million yuan, with net profits of 176.95 million yuan, reflecting significant growth rates of 26.43% and 42.46% respectively [4] - The company’s EBITDA is expected to reach 255.72 million yuan in 2025, with a steady increase in subsequent years [5] - The earnings per share (EPS) is projected to grow from 0.54 yuan in 2023 to 1.05 yuan in 2025 [5] Market Position - The company operates in the basic chemicals and chemical products industry, with a current market capitalization of approximately 4.78 billion yuan [7] - The company has a total share capital of 168.31 million shares, with a net asset value per share of 9.66 yuan [7]

Core Insights - China Mengniu Dairy Company Limited is actively advancing the A-round financing for its synthetic biology subsidiary, Hongmo Biotechnology, with a significantly increased valuation compared to the previous round [1][2] - The strategic focus on Human Milk Oligosaccharides (HMO) and innovative product development positions Mengniu favorably in the dairy industry [2] Group 1: Financing and Valuation - Hongmo Biotechnology is undergoing A-round financing, attracting multiple investment institutions for due diligence, indicating strong market interest [1] - The company completed a Pre-A round financing of over 100 million yuan in June 2024, led by CICC Qide Fund, with funds allocated for new product development and commercialization [1][2] Group 2: Strategic Development and Innovation - Mengniu's strategic layout for HMO dates back to 2016, establishing a comprehensive innovation system from basic research to industrialization [2] - Hongmo Biotechnology won the "Best Startup Brand Award" at the 2025 World Dairy Innovation Awards, marking a significant achievement for Chinese functional nutrition technology [2] - Mengniu has successfully integrated HMO technology into various products, including the Ruibaoen series of milk powder and the Future Star HMO children's liquid formula, demonstrating a proactive response to nutritional demands in the new health era [2]

Core Viewpoint - The company, Meihua Biological, demonstrated strong resilience and growth potential in its 2025 semi-annual report despite a complex market environment, achieving significant profit growth and substantial progress in its global expansion strategy [1] Financial Performance - The company reported operating revenue of 12.28 billion, a year-on-year decrease of 2.87%, while the net profit attributable to shareholders, excluding non-recurring gains and losses, reached 1.628 billion, a year-on-year increase of 24.98% [1] - The growth in net profit was primarily driven by increased product sales and cost optimization, with major products such as monosodium glutamate, 98% lysine, and feed-grade isoleucine showing sales growth [1][2] - The gross profit increased by 382 million, supporting the net profit growth [1] Global Expansion - The company made significant strides in its global layout, completing a cross-border acquisition on July 1, 2025, marking the transition from strategic planning to substantial operational implementation [1][2] - The acquisition provided over 30 core patents, enhancing the company's international competitiveness and filling knowledge gaps in the synthetic biology and amino acid fermentation industries [2] Operational Efficiency - The company optimized its global competitiveness by reducing the anti-dumping tax rate on lysine in the EU from an initial 84.8% to 47.7%, the lowest in the country [3] - Following the acquisition, the company established overseas production bases and strengthened its supply chain management by collaborating with global suppliers [3] Capacity Upgrade and Digital Transformation - The company invested 1.087 billion in project expenditures, achieving full production efficiency in the Tongliao monosodium glutamate capacity upgrade project [4] - The implementation of the MES system has improved production management efficiency, with inventory turnover days at 50 and accounts receivable turnover days at 9 [5] Research and Development - The company increased R&D investment, focusing on core technology platform construction and strain optimization, and established a trial production platform to support the commercialization of new products [6] - The company distributed a total cash dividend of 1.699 billion (including tax) and repurchased shares worth 571 million, totaling 2.270 billion, which accounted for 83% of the net profit attributable to shareholders for 2024 [6] Future Outlook - The achievements in various aspects such as product, cost, global layout, operational system, capacity upgrade, digital transformation, R&D investment, and intellectual property lay a solid foundation for the company's future development [7]

Group 1 - The stock price of Shengda Bio reported at 18.64 yuan as of August 18, 2025, with a decrease of 0.14 yuan, representing a decline of 0.75% from the previous trading day [1] - The company specializes in the research, production, and sales of biotin, folic acid, and other vitamin products, which are widely used in feed, food, and pharmaceutical industries [1] - Shengda Bio's industry classification falls under the chemical products sector, involving synthetic biology and vitamins concepts [1] Group 2 - Shengda Bio announced the redemption of structured deposits amounting to 80 million yuan, which matured on August 15, resulting in a total recovery of 80.1193 million yuan, aligning with expected returns [1] - On August 18, the net outflow of main funds was 6.7311 million yuan, with a cumulative net outflow of 17.9616 million yuan over the past five days [1]